Neurocrine Biosciences
NBIX
#1464
Rank
C$21.77 B
Marketcap
C$214.17
Share price
-1.19%
Change (1 day)
11.63%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): C$9.27

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$9.33. In 2025 the company made an earnings per share (EPS) of C$6.70 an increase over its 2024 EPS that were of C$4.70.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$9.2738.32%
2025C$6.7042.6%
2024C$4.7033.07%
2023C$3.5357.76%
2022C$2.2469.47%
2021C$1.32-78.21%
2020C$6.06990%
2019C$0.5681.82%
2018C$0.31-113.5%
2017C-$2.270.62%
2016C-$2.2557.28%
2015C-$1.4325.61%
2014C-$1.1418.84%
2013C-$0.96-1085.71%
2012C$0.09731

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
C$1.82-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$2.86-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$39.24 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
C$1.28-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.82-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$5.71-38.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
C-$10.50-212.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.65-71.61%๐Ÿ‡ฌ๐Ÿ‡ง UK